# Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

> **NCT07557420** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 21 (estimated)

## Conditions studied

- NMOSD
- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT07557420
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07557420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07557420, "Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07557420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*